

Figure 1. Structural diversification of pyrethroid insecticides. Early synthetic pyrethroids resulted from attempts to improve the photolability and relatively weak biocidal activity of the pyrethrins, a series of chrysanthemic acid esters naturally present in the flowers of chrysanthemum species. Two major historical landmarks in pyrethroids development are the incorporation of an α -cyano group (see Permethrin and Cypermethrin), and the commercialization of products containing pyrethroid materials enriched with the most potent stereoisomer as the active ingredient (see modern pyrethroids at bottom) (Katsuda 1999; Wood 2013; Wolansky and Harrill 2008).

Key for structures: 1. Allethrin; 2. Dimethrin; 3. Resmethrin; 4. Kadethrin; 5. Permethrin; 6. Cypermethrin; 7. Tefluthrin; 8. Bifenthrin; 9. Etofenprox; 10. Esfenvalerate; 11. Imiprothrin; 12. Acrinathrin.

Figure 2. Neurobehavioral signs of pyrethroid toxicity. This scheme is mostly based on cage-side observations of male rats carried out during time- and dose-response assays for eleven pyrethroids dissolved in corn oil (dose volume = 1 ml/kg) (Wolansky et al. 2006, 2007; Crofton et al. 1995; Wolansky and Harrill 2008; McDaniel and Moser 1993; Soderlund et al. 2002). The y-axis shows a relative severity scale for the intensity of the endpoint alteration as observed at different time points after dosing, giving a score = 1 at the time of apparent peak toxicity, and the x-axis thus shows the time elapsed between single-bolus, oral administration of PYR and clinical observations, expressed in hours. The syndrome progression over time is illustratively divided in phases (namely P-I to P-IV) which are observed as a function of the administered dose from 1/100 to ~1/5 rat oral LD₅₀ (see WHO 2005; Wolansky et al. 2006; Wolansky and Harrill 2008). The insert at right shows the progression of the syndrome when nearly-lethal doses are administered (Phase P-IVa).

Figure 3. Influence of isomer ratios on pyrethroid toxicity. This chart illustrates the impact of individual isomers on the lethality of different preparations of pyrethroids. The y-axis shows rat oral LD₅₀s for the active-isomer rich preparations of one noncyano compound, *cis*-isomer rich permethrin (80:20 *cis:trans* PERM), and three cyano-compounds, λ -cyhalothrin, β -cyfluthrin and esfenvalerate, compared to the least potent ratio of permethrin isomers (20:80 *cis:trans* PERM), and the corresponding parent cyano-compounds, cyhalothrin, cyfluthrin and fenvalerate (LD₅₀s taken from WHO 2005, and INCHEM 1990a).

Figure 4. Influence of purity and carrier on pyrethroid toxicity. The intrinsic toxicity of a neat permethrin material (i.e., no carrier; $LD_{50} > 20,000$ mg/Kg), expressed as oral LD_{50} , is compared to 40% w/v solutions prepared using petroleum, DMSO or corn oil ($LD_{50} = +8,000$, $+8,000$, and 396 mg/Kg, respectively). Formulation carrier may produce major changes in potency (INCHEM 1990a).

Figure 5. Influence of route of exposure and vehicle on pyrethroid toxicity. The first panel (panel A) on top shows the variation in potency observed by using different routes to administer allethrin in mice. Apparently equipotent, highly-effective doses (expressed in mg/kg bw) administered by each route are compared (Nishimura et al. 1984). Panel B shows the evident influence of dosing vehicle on deltamethrin potency in rats. Deltamethrin dissolved in corn oil was observed to be up to ~200-fold more potent in producing a motor activity decline than other vehicles (i.e., ED₅₀ from 5.1 to >1,000 mg/Kg). A similar trend is observed for LOEL estimates. Oral LOEL and ED₅₀ doses are expressed in mg/Kg (taken from Crofton et al. 1995).

Figure 6. Influence of the selected endpoint on potency estimates for bifenthrin neurotoxicity. Dose-response patterns observed in rats at ~4 hours after oral exposure to bifenthrin in corn oil using FOB neurobehavioral assays (Wolansky et al. 2007a). In all assays (save internal temperature changes), authors used a scoring scale from 1 (control-like performance) to 4 (severe impairment) (see Panel A) for the effects of 1, 6, 12, and 20 mg/Kg bifenthrin (ascending doses denoted as increasingly darker figure bars). Note the variability of lowest-effective doses across neurobehavioral domains. Handling and tail pinch response were mostly unaffected, though a low-effective dose for tremor, pawing (Panel A), and body temperature (Panel B) was observed at ~6 mg/kg, consistent with a low-effective, ED₃₀ dose of 3.2 mg/Kg (95% confidence interval: 2.6-3.8 mg/Kg) for alteration of motor activity as estimated in a prior bifenthrin study where similar dosing and testing conditions were used (Wolansky et al. 2006).

Figure 7. Influence of twelve determinants on pyrethroid potency in laboratory animals.

This figure (panels A-B) shows the influence that might be expected on potency estimations by using different experimental and biological conditions. As reviewed studies present more than one assay condition for each determinant examined (e.g., as occurred in the assessment of the influence of four different vehicles on DLM's ED₃₀ for motor activity in the study by Crofton et al., 1995), this graphical approach shows the expected relative impacts on potency estimates, from the least to the most sensitive study conditions. These determinants of toxicity are ordered from those producing the greatest impact at left to those at right from which only minor variations in potency would be expected across studies differing in design. Panel B allows for distinguishing differences among factors having 1-12-fold impact on potency.

Note: For factor “Age”, the alluded maximal effect would be only possible at oral exposure levels equivalent to $\geq 1/20$ LD₅₀ (see oral LD₅₀ for permethrin in rat pups and adults, in: http://www.epa.gov/teach/chem_summ/pyrethroids_summary.pdf).

References which data to construct this figure were taken from

Structure. Rat oral LD₅₀s observed across pyrethroid insecticides, from the least toxic compound (LD₅₀ > 10 g/Kg) to the most potent compound (LD₅₀ = 22 mg/Kg) (WHO 2005; Wolansky and Harrill 2008).

Isomer-ratio. Studies of the differential acute oral lethality of several preparations of permethrin differing in *cis*- and *trans*-isomer ratios in rats (taken from: INCHEM 1990a).

Formulation. Three studies were considered. A comparison of the lethality of two formulations of deltamethrin (Lepeshkin et al. 1992), a comparison of the neurotoxicity of two formulations of permethrin and fenvalerate in mice (Williamson et al. 1989), and a study of the comparative effects of two permethrin test materials (a technical grade preparation and a 40%-pure, commercial formulation) on motor activity in time-course and dose-response assays conducted in rats (Wolansky, unpublished data).

Dose-Volume. Study of the toxicity observed in rats after oral administration of bifenthrin in corn oil. The two dosing conditions examined in this study are compared, 1 vs. 5 ml/Kg (Wolansky et al. 2007).

Route. Studies of the toxic action of deltamethrin in rats (Crofton et al. 1995) and allethrin in mice (Nishimura et al. 1995) using different routes of single-dose, acute administration. Monitoring of motor activity in mazes was conducted in the former study, and observation of toxic signs and tremorigenic activity scoring was used in the latter.

Vehicle. Study of the influence of four vehicles used to dissolve the test compound on the neurobehavioral toxicity of deltamethrin in rats, using motor activity as an endpoint (Crofton et al. 1995).

Species. A mild trend for a higher vulnerability in animals of smaller body size is apparent (Narahashi 2000). According to a few studies of deltamethrin and cypermethrin, mice appear to be 2-4-fold more susceptible than rats (taken from: INCHEM 1990b; INCHEM 1990c).

Gender - Strain. Limited evidence suggests no relevant influence on pyrethroid neurotoxicity.

Age. Based on the lethal toxicity and the acoustic-evoked startle response assays conducted in infant, weanling and adult rats after a single, oral dose of DLM in corn oil (Sheets et al. 1994; Sheets 2000).

Metabolites. Limited information is available suggesting no or very low neurotoxicity potential of pyrethroid metabolites in small rodents (Soderlund et al. 2002; see also difference in LD₅₀ for deltamethrin and tralomethrin in section “Pyrethroid metabolites”).

Morbid Condition. No information is available.

Endpoint. Two FOB studies examining permethrin, cypermethrin (McDaniel and Moser 1993) and bifenthrin (Wolansky et al. 2007a) actions on young adult male rats under identical dosing conditions were taken into account. The figure shows a variation in minimum effective doses across endpoints in the bifenthrin study.

Room Temperature. Study of the differential oral lethality of resmethrin in adult rats tested at three ambient temperatures, 4°C, 20°C and 30°C (White et al. 1976).

Realistic vs. Laboratory-Controlled Exposures: Available data (Eriksson and Talts 2000; Tsuji et al. 2002) is still insufficient to draw conclusions on possible pyrethroid sensitization manifesting from early life exposures to low doses of pyrethroids.

Table 1. Impact of experimental and organismic factors on pyrethroid neurotoxicity. The table classifies each determinant of toxicity with respect to pyrethroid toxicokinetics (TK) or toxicodynamics (TD) in laboratory animals. A relative score for the impact of each factor on potency estimation is also provided (maximum factor-effect between brackets in third column). Lack of information on the potential impact of these determinants on single-chemical risk assessments is marked in the fourth column when applicable.

Note: data on cumulative risk of neurotoxicity of pesticides has been recently started to be generated. For a part of the listed TK and TD factors, the influence of the experimental and organismic determinants on pyrethroid potency has not been incorporated to animal-human extrapolation procedures yet.

*Little evidence suggest no evident toxicodynamics-related, age-effect for acute oral exposures to low-effective doses of individual pyrethroids in small rodents. Moreover, no information is available for the influence of aging on pyrethroid vulnerability.

**The PoD used in risk assessment is regularly derived from the most sensitive endpoint assay; there is no analysis available of endpoint sensitivity for a representative number of Type I, Type II, and Mixed Type I/II pyrethroids using a full dose range scheme of administered doses.

Figure 1. Structural diversification of pyrethroid insecticides.




Figure 1. Structural diversification of pyrethroid insecticides. Early synthetic pyrethroids resulted from attempts to improve the photolability and relatively weak biocidal activity of the pyrethrins, a series of chrysanthemic acid esters naturally present in the flowers of chrysanthemum species. Two major historical landmarks in pyrethroids development are the incorporation of an α -cyano group (see Permethrin and Cypermethrin), and the commercialization of products containing pyrethroid materials enriched with the most potent stereoisomer as the active ingredient (see modern pyrethroids at bottom) (Katsuda 1999; Wood 2013; Wolansky and Harrill 2008).

Key for structures: 1. Allethrin; 2. Dimethrin; 3. Resmethrin; 4. Kadethrin; 5. Permethrin; 6. Cypermethrin; 7. Tefluthrin; 8. Bifenthrin; 9. Etofenprox; 10. Esfenvalerate; 11. Imiprothrin; 12. Acrinathrin.

Figure 2. Neurobehavioral signs of pyrethroid toxicity.




Figure 2. Neurobehavioral signs of pyrethroid toxicity. This scheme is mostly based on cage-side observations of male rats carried out during time- and dose-response assays for eleven pyrethroids dissolved in corn oil (dose volume = 1 ml/kg) (Wolansky et al. 2006, 2007; Crofton et al. 1995; Wolansky and Harrill 2008; McDaniel and Moser 1993; Soderlund et al. 2002). The y-axis shows a relative severity scale for the intensity of the endpoint alteration as observed at different time points after dosing, giving a score = 1 at the time of apparent peak toxicity, and the x-axis thus shows the time elapsed between single-bolus, oral administration of PYR and clinical observations, expressed in hours. The syndrome progression over time is illustratively divided in phases (namely P-I to P-IV) which are observed as a function of the administered dose from 1/100 to ~1/5 rat oral LD₅₀ (see WHO 2005; Wolansky et al. 2006; Wolansky and Harrill 2008). The insert at right shows the progression of the syndrome when nearly-lethal doses are administered (Phase P-IVa).

Figure 3. Influence of isomer ratios on pyrethroid toxicity.




Figure 3. Influence of isomer ratios on pyrethroid toxicity. This chart illustrates the impact of individual isomers on the lethality of different preparations of pyrethroids. The y-axis shows rat oral LD₅₀s for the active-isomer rich preparations of one noncyano compound, *cis*-isomer rich permethrin (80:20 *cis:trans* PERM), and three cyano-compounds, λ-cyhalothrin, β-cyfluthrin and esfenvalerate, compared to the least potent ratio of permethrin isomers (20:80 *cis:trans* PERM), and the corresponding parent cyano-compounds, cyhalothrin, cyfluthrin and fenvalerate (LD₅₀s taken from WHO 2005, and INCHEM 1990a).

Figure 4. Influence of purity and carrier on pyrethroid toxicity.




Figure 4. Influence of purity and carrier on pyrethroid toxicity. The intrinsic toxicity of a neat permethrin material (i.e., no carrier; LD₅₀ >20,000 mg/Kg), expressed as oral LD₅₀, is compared to 40% w/v solutions prepared using petroleum, DMSO or corn oil (LD₅₀ = +8,000, +8,000, and 396 mg/Kg, respectively). Formulation carrier may produce major changes in potency (INCHEM 1990a).

Figure 6. Influence of the selected endpoint on potency estimates for bifenthrin neurotoxicity.




Figure 6. Influence of the selected endpoint on potency estimates for bifenthrin neurotoxicity.




Figure 6. Influence of the selected endpoint on potency estimates for bifenthrin neurotoxicity. Dose-response patterns observed in rats at ~4 hours after oral exposure to bifenthrin in corn oil using FOB neurobehavioral assays (Wolansky et al. 2007a). In all assays (save internal temperature changes), authors used a scoring scale from 1 (control-like performance) to 4 (severe impairment) (see Panel A) for the effects of 1, 6, 12, and 20 mg/Kg bifenthrin (ascending doses denoted as increasingly darker figure bars). Note the variability of lowest-effective doses across neurobehavioral domains. Handling and tail pinch response were mostly unaffected, though a low-effective dose for tremor, pawing (Panel A), and body temperature (Panel B) was observed at ~6 mg/kg, consistent with a low-effective, ED₃₀ dose of 3.2 mg/Kg (95% confidence interval: 2.6-3.8 mg/Kg) for alteration of motor activity as estimated in a prior bifenthrin study where similar dosing and testing conditions were used (Wolansky et al. 2006).

Figure 7. Influence of twelve determinants on pyrethroid potency in laboratory animals. Panel A.




Figure 7. Influence of twelve determinants on pyrethroid potency in laboratory animals. Panel B




Figure 7. Influence of twelve determinants on pyrethroid potency in laboratory animals. This figure (panels A-B) shows the influence that might be expected on potency estimations by using different experimental and biological conditions. As reviewed studies present more than one assay condition for each determinant examined (e.g., as occurred in the assessment of the influence of four different vehicles on DLM's ED₃₀ for motor activity in the study by Crofton et al., 1995), this graphical approach shows the expected relative impacts on potency estimates, from the least to the most sensitive study conditions. These determinants of toxicity are ordered from those producing the greatest impact at left to those at right from which only minor variations in potency would be expected across studies differing in design. Panel B allows for distinguishing differences among factors having 1-12-fold impact on potency.

Note: For factor "Age", the alluded maximal effect would be only possible at oral exposure levels equivalent to $\geq 1/20$ LD₅₀ (see oral LD₅₀ for permethrin in rat pups and adults, in: http://www.epa.gov/teach/chem_summ/pyrethroids_summary.pdf).

Figure 7. Influence of twelve determinants on pyrethroid potency in laboratory animals.

References which data to construct this figure were taken from

Structure. Rat oral LD₅₀s observed across pyrethroid insecticides, from the least toxic compound (LD₅₀ > 10 g/Kg) to the most potent compound (LD₅₀ = 22 mg/Kg) (WHO 2005; Wolansky and Harrill 2008).

Isomer-ratio. Studies of the differential acute oral lethality of several preparations of permethrin differing in *cis*- and *trans*-isomer ratios in rats (taken from: INCHEM 1990a).

Formulation. Three studies were considered. A comparison of the lethality of two formulations of deltamethrin (Lepeshkin et al. 1992), a comparison of the neurotoxicity of two formulations of permethrin and fenvalerate in mice (Williamson et al. 1989), and a study of the comparative effects of two permethrin test materials (a technical grade preparation and a 40%-pure, commercial formulation) on motor activity in time-course and dose-response assays conducted in rats (Wolansky, unpublished data). **Dose-Volume.** Study of the toxicity observed in rats after oral administration of bifenthrin in corn oil. The two dosing conditions examined in this study are compared, 1 vs. 5 ml/Kg (Wolansky et al. 2007).

Route. Studies of the toxic action of deltamethrin in rats (Crofton et al. 1995) and allethrin in mice (Nishimura et al. 1995) using different routes of single-dose, acute administration. Monitoring of motor activity in mazes was conducted in the former study, and observation of toxic signs and tremorigenic activity scoring was used in the latter.

Vehicle. Study of the influence of four vehicles used to dissolve the test compound on the neurobehavioral toxicity of deltamethrin in rats, using motor activity as an endpoint (Crofton et al. 1995).

Species. A mild trend for a higher vulnerability in animals of smaller body size is apparent (Narahashi 2000). According to a few studies of deltamethrin and cypermethrin, mice appear to be 2-4-fold more susceptible than rats (taken from: INCHEM 1990b; INCHEM 1990c).

Gender - Strain. Limited evidence suggests no relevant influence on pyrethroid neurotoxicity.

Age. Based on the lethal toxicity and the acoustic-evoked startle response assays conducted in infant, weanling and adult rats after a single, oral dose of DLM in corn oil (Sheets et al. 1994; Sheets 2000).

Metabolites. Limited information is available suggesting no or very low neurotoxicity potential of pyrethroid metabolites in small rodents (Soderlund et al. 2002; see also difference in LD₅₀ for deltamethrin and tralomethrin in section "Pyrethroid metabolites").

Morbid Condition. No information is available.

Endpoint. Two FOB studies examining permethrin, cypermethrin (McDaniel and Moser 1993) and bifenthrin (Wolansky et al. 2007a) actions on young adult male rats under identical dosing conditions were taken into account. The figure shows a variation in minimum effective doses across endpoints in the bifenthrin study.

Room Temperature. Study of the differential oral lethality of resmethrin in adult rats tested at three ambient temperatures, 4°C, 20°C and 30°C (White et al. 1976).

Realistic vs. Laboratory-Controlled Exposures: Available data (Eriksson and Talts 2000; Tsuji et al. 2002) is still insufficient to draw conclusions on possible pyrethroid sensitization manifesting from early life exposures to low doses of pyrethroids

Impact of experimental and organismic factors on pyrethroid neurotoxicity.

Toxicological Aspect	Toxicity Determinant	Maximum factor-effect in single-compound assays (pyrethroids' case)	Is consideration of the impact of these study design aspects a standard procedure in risk assessment for pesticides?
Toxicokinetics	Chemical Structure	++++++ (500-fold)	Yes
	Isomer Composition	+++ (25-fold)	Yes
	Formulation/Purity	+++ (50-fold)	NO
	Vehicle	++++++ (200-fold)	NO
	Route of Exposure	+++ (28-fold)	Yes
	Dose Volume	+ (3-fold)	NO
	Dosing Solution	+ ($\leq$ 2-fold)	NO
	Metabolic Activation	+ ($\leq$ 1.5-fold)	NO
	Age (Detoxification System Maturation)	++ (10-fold)*	YES
Toxicodynamics	Species (Rodent)	++ (4-fold)	YES
	Age (Nervous System Development)	No effect? *	YES*
	Endpoint	+ (3-fold)	NO**
	Physiological Status	+ (2-fold)	NO
	Morbidity	No data available	NO
Testing Room	Ambient Temperature	++ (6-fold)	NO
History of pesticide exposure episodes (from gestation to adulthood)	Realistic Sequential Exposures vs. Laboratory Controlled Acute Exposure	Little data available	NO

Table 1. Impact of experimental and organismic factors on pyrethroid neurotoxicity. The table classifies each determinant of toxicity with respect to pyrethroid toxicokinetics (TK) or toxicodynamics (TD) in laboratory animals. A relative score for the impact of each factor on potency estimation is also provided (maximum factor-effect between brackets in third column). Lack of information on the potential impact of these determinants on single-chemical risk assessments is marked in the fourth column when applicable.

Note: data on cumulative risk of neurotoxicity of pesticides has been recently started to be generated. For a part of the listed TK and TD factors, the influence of the experimental and organismic determinants on pyrethroid potency has not been incorporated to animal-human extrapolation procedures yet.

*Little evidence suggest no evident toxicodynamics-related, age-effect for acute oral exposures to low-effective doses of individual pyrethroids in small rodents. Moreover, no information is available for the influence of aging on pyrethroid vulnerability.

**The PoD used in risk assessment is regularly derived from the most sensitive endpoint assay; there is no analysis available of endpoint sensitivity for a representative number of Type I, Type II, and Mixed Type I/II pyrethroids using a full dose range scheme of administered doses.